| Original language | English |
|---|---|
| Pages (from-to) | 477-479 |
| Number of pages | 3 |
| Journal | Drug Design, Development and Therapy |
| Volume | 13 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science
- Drug Discovery
Cite this
Spagnuolo, V., Galli, L., Poli, A., Bigoloni, A., Fumagalli, L., Gianotti, N., Nozza, S., Ferrari, D., Locatelli, M., Lazzarin, A., & Castagna, A. (2019). A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study. Drug Design, Development and Therapy, 13, 477-479. https://doi.org/10.2147/DDDT.S192124